Neoadjuvant KN026 Plus Docetaxel Demonstrate Early Activity in HER2+ Breast Cancer

A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.

Related Keywords

Lin Xiaoxi Ma ,European Society For Medical Oncology Congress ,Eastern Cooperative Oncology Group ,Crystal Light ,Medical Oncology ,Udocetaxel ,Kn026 ,Bispecific Antibody ,Neoadjuvant Treatment ,Breast Cancer ,Ther2 ,Her2 Positive ,Hormone Receptor Positivity ,